Skip to content
value.today

TP Therapeutics, INC

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2013
Total raised
$126 M
3 rounds on record
Latest round
$80 M
Oct 2018
First round on record
Dec 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TP Therapeutics, INC
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$80 MNo. 3$50 to $250 million

TP Therapeutics, INC: Raise no. 3, Oct 2018

Investors in this round

16 investors had bought by the notice of Oct 30, 2018: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for TP Therapeutics, INC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Athena Maria Countouriotis · Executive Officer, Director
  • Jingrong Cui · Executive Officer, Director
  • Brett J. Zbar · Director
  • Carl Maria Gordon · Director
  • Hongbo Maria Lu · Director
  • Kenneth Fong · Director
  • Lewis J. Shuster · Director
  • Robert J. Adelman · Director
  • Sheila K. Gujrathi · Director
  • Simeon Maria George · Director
  • Yishan Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Athena Maria Countouriotis, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 30, 2018. Read the notice at the SEC.

equitySEC
May 2017$45 MNo. 2$10 to $50 million

TP Therapeutics, INC: Raise no. 2, May 2017

Investors in this round

13 investors had bought by the notice of May 25, 2017: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for TP Therapeutics, INC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingrong Cui · Executive Officer, Director
  • Yishan Li · Executive Officer, Director
  • Bihua Chen · Director
  • George Lee · Director
  • Kenneth Fong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Yishan (Peter) Li, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 25, 2017. Read the notice at the SEC.

equitySEC
Dec 2013$1 MNo. 1Under $2 million

TP Therapeutics, INC: Raise no. 1, Dec 2013

Investors in this round

8 investors had bought by the notice of Jan 6, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for TP Therapeutics, INC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jingrong Cui · Executive Officer, Director
  • Yishan Li · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Yishan Li, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 6, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TP Therapeutics, INC chose not to state its revenue in its newest notice of a funding round (Oct 2018).

    SEC Form D · Oct 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2018

That is all the official record says: TP Therapeutics, INC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in TP Therapeutics, INC
InvestorKindAmountRoundRoleSource
GSK PLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, director (Form 3, 2019)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TP Therapeutics, INC
NameRoleNamed in
Athena Maria CountouriotisExecutive officerOct 2018
Jingrong CuiExecutive officerOct 2018
Yishan LiExecutive officerMay 2017
Athena Maria CountouriotisDirectorOct 2018
Brett J. ZbarDirectorOct 2018
Carl Maria GordonDirectorOct 2018
Hongbo Maria LuDirectorOct 2018
Jingrong CuiDirectorOct 2018
Kenneth FongDirectorOct 2018
Lewis J. ShusterDirectorOct 2018
Robert J. AdelmanDirectorOct 2018
Sheila K. GujrathiDirectorOct 2018
Simeon Maria GeorgeDirectorOct 2018
Yishan LiDirectorOct 2018
Bihua ChenDirectorMay 2017
George LeeDirectorMay 2017